328233-23-4

Basic information

• Product Name: trans-1'-Oxo-spiro[cyclohexane-1,3'(1'H)-furo[3,4-c]pyridine]-4-carboxylic acid
• Synonyms: TRANS-1''-OXO-SPIRO[CYCLOHEXANE-1,3''(1''H)-FURO[3,4-C]PYRIDINE]-4-CARBOXYLIC ACID
• CAS NO: 328233-23-4
• Molecular Formula: C₁₃H₁₃NO₄
• Molecular Weight: 247.249
• Mol File: 328233-23-4.mol

Chemical Properties

• Melting Point: 240-244 °C
• Boiling Point: 538.7 °C at 760 mmHg
• Flash Point: 279.6 °C
• Appearance: /
• Density: 1.41
• CAS DataBase Reference: trans-1'-Oxo-spiro[cyclohexane-1,3'(1'H)-furo[3,4-c]pyridine]-4-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: trans-1'-Oxo-spiro[cyclohexane-1,3'(1'H)-furo[3,4-c]pyridine]-4-carboxylic acid(328233-23-4)
• EPA Substance Registry System: trans-1'-Oxo-spiro[cyclohexane-1,3'(1'H)-furo[3,4-c]pyridine]-4-carboxylic acid(328233-23-4)

Safety Data

• Hazardous Substances Data: 328233-23-4(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
Trans-1'-Oxo-spiro[cyclohexane-1,3'(1'H)-furo[3,4-c]pyridine]-4-carboxylic acid is used as a building block in organic synthesis for the creation of more complex molecules. Its unique spirocyclic structure and carboxylic acid group provide opportunities for further chemical modifications and the development of novel compounds with specific properties.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, trans-1'-Oxo-spiro[cyclohexane-1,3'(1'H)-furo[3,4-c]pyridine]-4-carboxylic acid is used as a potential starting material for the design and synthesis of new pharmaceutical agents. Its unique structure may offer novel binding interactions with biological targets, leading to the discovery of new drugs with improved efficacy and selectivity.
Used in Drug Development:
Trans-1'-Oxo-spiro[cyclohexane-1,3'(1'H)-furo[3,4-c]pyridine]-4-carboxylic acid is utilized in drug development as a candidate compound with potential biological activities. Its distinctive spirocyclic system may confer interesting pharmacological properties, making it a valuable asset in the search for new therapeutic agents.
Used in Chemical Research:
In the realm of chemical research, trans-1'-Oxo-spiro[cyclohexane-1,3'(1'H)-furo[3,4-c]pyridine]-4-carboxylic acid serves as a subject of study for understanding the properties and reactivity of spirocyclic systems. Its unique structure allows researchers to explore new reaction pathways and develop innovative synthetic methods for the preparation of complex organic molecules.
Overall, trans-1'-Oxo-spiro[cyclohexane-1,3'(1'H)-furo[3,4-c]pyridine]-4-carboxylic acid is a novel and intriguing chemical compound with a wide range of potential applications in various fields, including organic synthesis, medicinal chemistry, drug development, and chemical research. Its unique spirocyclic structure and carboxylic acid group make it a valuable building block for the creation of more complex molecules and a promising candidate for the development of new pharmaceutical agents.

Upstream product

• 3034-31-9 N-phenylisonicotinamide 
• 17159-79-4 ethyl 4-oxocyclohexane-1-carboxylate 
• 328233-22-3 trans-3-oxo-3H-spiro[6-aza-2-benzofuran-1,1'-cyclohexane]-4'-carbonitrile 
• 569351-62-8 1'-oxospiro[1,3'-cyclohexane(1'H)-furo[3,4-c]pyridine]-4-carboxylic acid 
• 870466-68-5 C₁₇H₂₁NO₄ 

Downstream Products

• 328232-95-7 MK-0557 
• 1195313-76-8 trans-3-oxo-N-(5-phenylpyridin-2-yl)-3H-spiro[6-aza-2-benzofuran-1,1'-cyclohexane]-4'-carboxamide 
• 478014-55-0 trans-3-oxo-N-(2-phenyl-1,3-thiazol-4-yl)-3H-spiro[6-aza-2-benzofuran-1,1'-cyclohexane]-4'-carboxamide 
• 1195313-90-6 trans-N-[1-(3-fluorophenyl)-1H-pyrazol-3-yl]-3-oxo-3H-spiro[6-aza-2-benzofuran-1,1'-cyclohexane]-4'-carboxamide 
• 328232-93-5 trans-3-oxo-N-(1-phenyl-1H-pyrazol-3-yl)-3H-spiro[6-aza-2-benzofuran-1,1'-cyclohexane]-4'-carboxamide 
• 1195313-81-5 trans-3-oxo-N-(1-phenyl-1H-pyrazol-4-yl)-3H-spiro[6-aza-2-benzofuran-1,1'-cyclohexane]-4'-carboxamide 
• 328232-76-4 trans-3-oxo-N-(5-phenylpyrimidin-2-yl)-3H-spiro[6-aza-2-benzofuran-1,1'-cyclohexane]-4'-carboxamide 
• 328232-97-9 trans-3-oxo-N-(5-phenylisoxazol-3-yl)-3H-spiro[6-aza-2-benzofuran-1,1'-cyclohexane]-4'-carboxamide 
• 328232-99-1 trans-3-oxo-N-(2-phenyl-2H-1,2,3-triazol-4-yl)-3H-spiro[6-aza-2-benzofuran-1,1'-cyclohexane]-4'-carboxamide 
• 1195313-73-5 trans-3-oxo-N-(3-phenyl-1H-pyrazol-5-yl)-3H-spiro[6-aza-2-benzofuran-1,1'-cyclohexane]-4'-carboxamide 
• 328232-94-6 trans-N-[1-(4-fluorophenyl)-1H-pyrazol-3-yl]-3-oxo-3H-spiro[6-aza-2-benzofuran-1,1'-cyclohexane]-4'-carboxamide 
• 1195313-71-3 trans-3-oxo-N-(5-phenylpyrazin-2-yl)-3H-spiro[6-aza-2-benzofuran-1,1'-cyclohexane]-4'-carboxamide 
• 1192312-60-9 C₂₃H₁₉FN₄O₃ 
• 1192312-62-1 C₂₄H₂₁FN₄O₃ 

Relevant articles and documents

Discovery of trans-N-[1-(2-fluorophenyl)-3-pyrazolyl]-3-oxospiro[6-azaisobenzofuran-1(3H),1′-cyclohexane]-4′-carboxamide, a potent and orally active neuropeptide Y Y5 receptor antagonist

A series of trans-3-oxospiro[(aza)isobenzofuran-1(3H),1′-cyclohexane]-4′-carboxamide derivatives were synthesized to identify potent NPY Y5 receptor antagonists. Of the compounds, 21j showed high Y5 binding affinity, metabolic stability and brain and cerebrospinal fluid (CSF) penetration, and low susceptibility to P-glycoprotein transporters. Oral administration of 21j significantly inhibited the Y5 agonist-induced food intake in rats with a minimum effective dose of 1 mg/kg. This compound was selected for proof-of-concept studies in human clinical trials.

Identification of positron emission tomography ligands for NPY Y5 receptors in the brain

A series of trans-3-oxospiro[(aza)isobenzofuran-1(3H),1′-cyclohexane]-4′-carboxamide derivatives were synthesized and profiled for NPY Y5 binding affinity, brain and CSF penetrability in rats, and susceptibility to human and mouse P-glycoprotein transporters in order to develop a PET ligand. Compound 12b exhibited an acceptable profile for a PET ligand, and [11C]12b was successfully utilized in clinical settings as a Y5 PET ligand.

Practical synthesis of a neuropeptide Y antagonist via stereoselective addition to a ketene

The synthesis of neuropeptide Y antagonist 1, currently under clinical investigation for the treatment of obesity, is described. The convergent synthesis from trans-spirolactone carboxylic acid intermediate 2a and aminopyrazole 3 is predicated on a stereo